John Newman
Stock Analyst at Canaccord Genuity
(2.17)
# 2,803
Out of 5,172 analysts
93
Total ratings
45.12%
Success rate
-6.72%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCRB Seres Therapeutics | Maintains: Buy | $22 | $8.50 | +158.82% | 11 | Mar 13, 2026 | |
| CADL Candel Therapeutics | Maintains: Buy | $25 | $4.97 | +403.02% | 3 | Mar 13, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.07 | +576.33% | 4 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $89.27 | +91.55% | 9 | Mar 11, 2026 | |
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.91 | +22.20% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $6.92 | +160.12% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $114.77 | +13.27% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $732.87 | +44.23% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.15 | +94.17% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $94.77 | +32.95% | 1 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $9.07 | +131.53% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.34 | +497.01% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.51 | +560.52% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.95 | +426.32% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.86 | +57.93% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.82 | +174.96% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $1.81 | +1,391.71% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $14.02 | - | 1 | Sep 13, 2017 |
Seres Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $22
Current: $8.50
Upside: +158.82%
Candel Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $25
Current: $4.97
Upside: +403.02%
Allogene Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $14
Current: $2.07
Upside: +576.33%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $171
Current: $89.27
Upside: +91.55%
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.91
Upside: +22.20%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $6.92
Upside: +160.12%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $114.77
Upside: +13.27%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $732.87
Upside: +44.23%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.15
Upside: +94.17%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $94.77
Upside: +32.95%
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $9.07
Upside: +131.53%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.34
Upside: +497.01%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.51
Upside: +560.52%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.95
Upside: +426.32%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.86
Upside: +57.93%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.82
Upside: +174.96%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $1.81
Upside: +1,391.71%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $14.02
Upside: -